Journal
Found Review 2026: $359 Month to Month or $239 on 12 Months, and the Prescriber-Chooses Caveat
Released: Last reviewed:
Short answer — August 2026
Found's cash ladder for compounded tirzepatide, read on October 15, 2026: $219 for the first 28-day cycle, then $359 month to month, $309 on a 3-month term, $289 on 6 months and $239 on 12 months, each covering clinical care, medication and membership. That is a $120 spread between month to month and the 12-month term, and a step up from the $169 prepaid / $289 monthly structure we captured in July 2026. Found also runs an insurance track (our July 2026 capture: $99 prepaid annual, or $199 monthly plus copay; not re-read), which makes it one of the few compounded-era programs with a real coverage pathway. The caveat that reframes everything: Found's model is personalized prescribing across drug classes, and the clinician may recommend a non-GLP-1 medication — which for a buyer shopping for tirzepatide specifically is a risk worth pinning before any long-term commitment.
The structure: a steep term ladder
Two things stand out. First, the term ladder is steep: $359 per cycle month to month against $239 on the 12-month term, and even the 12-month rate sits above the flat monthly prices other programs printed on October 15 (Eden lists tirzepatide at $129 a month with no membership; our editor's pick NexLife lists $129 monthly and $115 on 12 months). Found's month-to-month $359 is near brand territory: LillyDirect lists Zepbound at $299 to $449 a month by dose under its current refill terms. Second, the cycle is 28 days, so a year holds thirteen charges, not twelve — budget on that. The insurance track remains the quiet asset: for a covered buyer it routes toward the coverage math few compounded programs even attempt.
The caveat, the questions, and the verdict
Personalized prescribing means the intake's output is the clinician's call — a defensible clinical model, and a real mismatch risk for the buyer who arrived for a specific molecule at a specific price. So the pre-payment questions: if the recommendation isn't the GLP-1 I came for, what are my options and refund terms on the prepaid plan? What exactly is my medication and dose before the annual charge, in writing? Plus the standards: pharmacy name, exit mechanics, credit-card rail on any prepayment. Verdict by buyer: the insurance-eligible land well here; the cash tirzepatide shopper finds lower flat monthly prices elsewhere on the October 15 reads; and the flexibility buyer should read $359 as the price of not committing — Found's ladder is one of the clearest printouts of what this market charges for flexibility.
Questions people ask
How much does Found cost for GLP-1s?
For compounded tirzepatide on the cash-pay track, Found's page read on October 15, 2026 lists $219 for the first month, then $359 per 28-day cycle month to month, or $309, $289 and $239 per cycle on 3-, 6- and 12-month terms, covering clinical care, medication and membership. Semaglutide and insurance-track prices were not re-read; our July 2026 capture had the insurance track at $99/month prepaid annual or $199/month plus copay.
Does Found guarantee I'll get tirzepatide?
No — Found's model is personalized prescribing across drug classes, and the clinician may recommend a different medication. Before any prepayment, get in writing: your specific medication and dose, and the refund terms if the recommendation isn't the GLP-1 you enrolled for.
Is Found's 12-month plan a good deal?
At $239 per 28-day cycle (October 15, 2026 read), Found's 12-month tirzepatide rate is well below its own $359 month-to-month price but above the flat monthly prices several programs print, such as Eden's $129 and NexLife's $129 monthly. Found's real edge is its insurance track; its cash month-to-month price is the flexibility ceiling, not a contender. The older $169 prepaid plan from our July 2026 capture no longer appears on the page we read.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.